CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expressionErika Tissino, Antonella Zucchetto, Federico Pozzo et al.|Blood|2020Cited by 62
<scp><i>TP53</i></scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Massimo Gentile, Giovanni Del Poeta et al.|American Journal of Hematology|2021Cited by 13
<i>XPO1</i> mutations identify early‐stage <scp>CLL</scp> characterized by shorter time to first treatment and enhanced <scp>BCR</scp> signallingRiccardo Moia, Gianluca Gaïdano, Lodovico Terzi di Bergamo et al.|British Journal of Haematology|2023Cited by 7
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligandsErika Tissino, Valter Gattei, Annalisa Gaglio et al.|Leukemia|2024Cited by 6
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Francesca Romana Mauro, Candida Vitale et al.|Leukemia|2025Cited by 5